KRAS and cancer: Srivastava et al. [29] reported, in Oxaliplatin pretreated KRAS-mutated lung cancer mouse, chimeric antigen receptor-modified T cells (CAR-T cells) therapy increased cancer sensitivity to anti-PD-L1 therapy.